BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Efficacy and safety study, in collaboration with MD Anderson Cancer Center,

will assess BL-8040 as combination treatment with immunosuppressants

Interim results of study, in patients with hypoplastic myelodysplastic

syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016